Trevor J Henderson
Trevor Henderson is the Creative Services Director for the Laboratory Products Group at LabX Media Group. With over two decades of experience, he specializes in scientific and technical writing, editing, and content creation. His academic background includes training in human biology, physical anthropology, and community health. Since 2013, he has been developing content to engage and inform scientists and laboratorians.
Articles by Trevor J Henderson
| 6 min read
There are vastly more possible drug-like molecules than any chemist could ever screen. Here is how generative models are actually being used to search that space, and where the approach still runs into hard limits.
| 8 min read
No single rulebook governs artificial intelligence in drug development. Instead, three different regulators are moving at three different speeds, and knowing exactly where each one stands is now part of the job.
| 7 min read
FDA's paper trail on artificial intelligence is longer and more scattered across centers than most bench scientists realize. Here is what each document actually says, and which ones apply to drugs rather than devices.
| 6 min read
Decades of genomic and clinical research were not conducted equally across populations. AI trained on that history inherits it, which raises a real question: will AI-discovered medicines work equally well for everyone?
| 6 min read
Patent law was not written with generative models in mind. As AI becomes central to drug discovery, questions about ownership, inventorship, and data sharing are being answered in real time, not always consistently.
| 6 min read
A model that says a molecule scores 0.87 has not told a chemist anything actionable. Explainability is what turns a score into a design decision, and it is harder to get right than it sounds.
| 8 min read
Antibody drug discovery poses a different set of AI problems than small molecules. Here is what is actually working for biologics, and how far it is from designing an antibody from scratch.
| 7 min read
Lead optimization is where most drug programs grind through thousands of analogues. AI is not replacing that chemistry, but it is changing how candidates are chosen and prioritized.
| 7 min read
The diffusion model revolution behind AI image generation has a direct parallel in molecular design. Here is how it works and how far the generated molecules are from being drugs.
| 7 min read
AlphaFold is the most significant structural biology tool in a generation. Whether it has changed drug discovery at the same scale is a more nuanced question, and the honest answer separates real impact from hype.
| 8 min read
Generative models can now design novel drug-like molecules on demand. What they generate reliably, and what medicinal chemists still have to fix, is the real story.
| 8 min read
AI is now embedded across the drug discovery pipeline. This guide maps the full arc, where the technology delivers, where it still falls short, and what the science actually shows.
